Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Rights to cantuzumab mertansine returned to ImmunoGen

Jan. 28, 2003

Single-agent epratuzumab trial closes

Jan. 28, 2003

Pivotal OvaRex trials begin enrollment

Jan. 27, 2003

G17DT recommended for orphan drug status in E.U.

Jan. 24, 2003

New data on cantuzumab mertansine in tumors expressing the CanAg antigen

Jan. 22, 2003

CytRx grants option to PSMA for TranzFect adjuvant

Jan. 20, 2003

Enrollment complete in phase I/II trial of TheraCIM h-R3 in head and neck cancer

Jan. 17, 2003

YM BioSciences' prostate cancer vaccine trial completes enrollment

Jan. 17, 2003

Epimmune cleared to begin phase I/II trials of EP-2101

Jan. 15, 2003

Phase I/II results announced for Genzyme Molecular Oncology's melanoma vaccine

Jan. 14, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...